The medication is used to help ease the overall symptom load related to moderate discomfort that is linked to involuntary muscle tension. Its application spans core therapeutic domains involving the digestive system, the kidneys, and the gallbladder.

Painful Spasms of Visceral Organs

This medication is relevant for easing symptom clusters that include colicky or cramping pain, which arises from smooth muscle spasms in internal organs. It is commonly used for conditions presenting with acute episodes, such as renal colic (ureteric spasms) and painful spasms of the biliary tract. It supports relief in these contexts by combining pain-easing properties with spasm-easing properties, and may help ease the overall symptom load related to the acute spasmodic discomfort.

Management of Moderate Pain and Co-occurring Fever

Spasmalgin is commonly used when discomfort is moderate in intensity and is relevant when symptomatic support beyond general relief is appropriate. It also plays a role in managing associated fever that can accompany acute spasmodic episodes. This approach may assist with maintaining functional stability and contributes to easing overall discomfort during periods of sudden, painful intensification.

Quick Fact: Relief for Acute Discomfort
Conditions	Renal colic, Biliary tract spasms, Gastro-intestinal spasms
Symptom Profile	Moderate pain, Colic, Cramping, Co-occurring fever
Benefit	Supports symptomatic relief for pain and spasm

Regulatory References

1. Analgesic and antispasmodic for the digestive system, the kidneys and the gall bladder

The eligibility for using Spasmalgin is strictly defined by regulatory guidelines, which establish absolute prohibitions and conditional use based on the combination of its four active ingredients.

Populations Who Must Not Use Spasmalgin (Contraindicated)

Official labeling mandates that the medicine is contraindicated for several groups:

• Age and Metabolism: Children under 12 years of age; adolescents aged 12 to 18 years following tonsillectomy or adenoidectomy; and individuals identified as CYP2D6 ultra-rapid metabolizers of Codeine.
• Reproductive Status: Women who are pregnant or are breastfeeding.
• Pre-existing Conditions: Patients with known hypersensitivity to any component; acute respiratory depression; angle-closure glaucoma; paralytic ileus or pyloric stenosis; or prostatic enlargement that may lead to urinary retention.

Populations Requiring Conditional Use

Use is subject to caution or potential dosage reduction in specific populations, as documented in regulatory warnings:

• Organ Function: Patients with impaired hepatic function or impaired renal function.
• Age: Older adults, due to increased sensitivity and risk of age-related organ impairment.
• Other Conditions: Individuals with decreased respiratory reserve, hypothyroidism, or raised intracranial pressure. Use is limited to the shortest duration for acute pain.

Interactions with other medicines and products

Spasmalgin is a fixed-dose combination, and its official interaction profile is defined by the four active components: Paracetamol, Codeine, Papaverine, and Atropine. The documented interactions fall into categories of metabolic processing and additive pharmacodynamic effects.

---

Contraindicated Combinations and Use Restrictions

• Co-administration of the Codeine component with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited. This restriction extends for 14 days after MAOI use is discontinued.
• Use is formally restricted in individuals who are CYP2D6 ultra-rapid metabolizers due to the high risk of opioid toxicity resulting from rapid metabolic conversion.

---

Metabolic (Exposure-Altering) Interactions

• CYP2D6 and CYP3A4 inhibitors (such as Amiodarone or Ritonavir) are documented to increase the exposure of Codeine while decreasing the formation of its active metabolite.
• Conversely, enzyme inducers (such as Rifampicin) may decrease Codeine levels. The absorption of Paracetamol may be accelerated by agents like Metoclopramide and reduced by Cholestyramine.

---

Pharmacodynamic (Additive) Interactions

• Co-administration of Codeine with CNS Depressants (including alcohol) results in severe additive effects, including documented respiratory depression and profound sedation.
• Combining the anticholinergic components (Atropine, Papaverine) with other anticholinergic agents can lead to cumulative effects, such as increased risk of urinary retention.
• Prolonged, regular use of Paracetamol with Warfarin may enhance the anticoagulant effect and increase bleeding risk.

Dual Central Nociceptive Signal Modulation

Central action involves two complementary analgesic mechanisms. The Codeine component, via its active metabolite, acts as an agonist at mu-opioid receptors in the Central Nervous System (CNS), suppressing neurotransmitter release to inhibit the transmission of nociceptive signals. Simultaneously, Paracetamol works by inhibiting the peroxidase site of COX enzymes in the brain and spinal cord, which modulates central prostaglandin production and influences the hypothalamic temperature set-point. This combined CNS activity results in multifaceted central signal suppression.

Coordinated Peripheral Spasmolysis

Peripheral action against spasm is managed by two distinct, synergistic mechanisms targeting visceral smooth muscle. Atropine provides neurogenic spasmolysis by acting as a competitive antagonist at muscarinic receptors, blocking the nerve signals that initiate excessive muscle tone. This action is complemented by Papaverine, which provides myogenic relaxation by inhibiting Phosphodiesterase (PDE) enzymes, leading to increased intracellular cyclic nucleotides ( cAMP/ cGMP) that decreases the contractile state of the muscle fiber.

Mechanistic Constraints

The activity in central nociceptive pathways of Codeine is strictly dependent on the CYP2D6 enzyme for conversion into its active form; thus, reduced enzyme function may result in reduced activity at the mu-opioid receptor. Paracetamol’s COX inhibition is functionally weaker in peripheral tissues due to high local peroxide concentrations, resulting in limited anti-inflammatory pathway modulation compared to its primary central nociceptive-modulating activity.

Administration and Dosage Principles

Spasmalgin is an oral administration medicine available as a fixed-dose combination tablet. Usage is characterized by specific parameters regarding quantity, frequency, timing, and duration.

Standard Dosing and Limits

For adults, the typical single dose is 1 to 2 tablets. The maximum total daily intake is limited to 8 tablets within any 24-hour period. The medicine is generally administered up to 3 times per day.

Administration Timing and Conditions

To ensure proper intake, the tablet is administered with or immediately after a meal and swallowed with water. A specific condition for use is the required interval before taking other oral products: the medicine is taken at least two hours before the administration of antacids or osmotic laxatives. If a dose is missed, it should be taken when remembered, but two doses must not be taken simultaneously to compensate.

Duration and Population Rules

Spasmalgin is intended for short-term use only. The treatment course does not extend beyond three consecutive days without a clinical reassessment. The product is not intended for use in children under 12 years of age.

Research Evidence / Overview of Studies for Spasmalgin

---

Evidence for use in Smooth Muscle Spasms of the Gastrointestinal Tract

Research examined Spasmalgin in conditions characterized by outcomes related to physical discomfort and episodic or acute changes within the digestive system. Studies included both randomized, controlled trials and observational settings. These trials typically monitored patient-reported outcomes describing perceived discomfort and severity of conditions involving periods of heightened symptoms over short or defined time intervals.

The findings describe patterns observed in the studies where research described changes in measurements taken during the study period. Research highlights changes related to outcomes describing episodic or acute changes in symptoms reported by the observed populations. Study results reflect the specific conditions under which they were conducted.

Evidence for use in Spastic Conditions of the Urinary and Biliary Tracts

Spasmalgin was evaluated in research exploring its study in conditions involving periods of heightened symptoms within the urinary and biliary systems. These investigations often focused on outcomes reflecting systemic or functional imbalance and were relevant in trials assessing short-term or episodic symptom patterns.

Studies report how symptoms evolved in the observed populations during episodes where symptoms become more noticeable. Research describes patterns related to outcomes linked to inflammatory or irritative states in these organ systems. Research describes patterns that were observed in some studies regarding changes in measurements of physical discomfort.

Long-term Studies and Follow-up

Research exploring short-term symptom changes was applied in studies examining patient-reported experiences, but long-term effects are not fully established for Spasmalgin. Most existing trials have follow-up durations that were limited, meaning comprehensive information on what happens after the initial treatment period concludes is not yet available. Research is ongoing to better understand these extended-duration outcomes.

What is Still Uncertain about Spasmalgin

This overview highlights several areas where the evidence is limited. The findings were mixed in some investigations, especially when comparing different study designs or patient groups, meaning subgroup findings are uncertain. The full duration of any observed changes is not well understood because follow-up durations were limited. Research provides context but not individual predictions. Findings describe group patterns, not personal outcomes; more research is needed to fully characterize the changes observed and to reduce the variability noted across the existing research landscape.

Key Studies & References

1. Assessment of Long-Term Outcomes and Durability of Response to Compound X for Functional Gastrointestinal Disorders (Observational Study)

Common questions about Spasmalgin (FAQ)

---

Q: How long does it typically take for Spasmalgin to start working?

Information from pharmacokinetic studies indicates that the Paracetamol component reaches its highest concentration in the bloodstream within 10 to 60 minutes. The Codeine component typically reaches its peak concentration around one hour after taking the tablet. This information describes the timeline for the body's absorption of the active ingredients.

Q: How long does the pain relief from Spasmalgin usually last?

The duration of pain relief is related to the time it takes for the active ingredients to be processed by the body. Official data on the analgesic component reports a typical duration of effect of approximately four hours.

Q: Does taking Spasmalgin with food affect how well it works?

The official instructions for this medicine state that the tablets should be administered with or immediately after a meal and swallowed with water. This method of administration is intended to ensure proper intake and may help minimize potential gastrointestinal discomfort.

Q: What is the chemical or category name for the pain-relieving part of Spasmalgin?

The pain-relieving components of this fixed-dose combination are Paracetamol (a synthetic compound) and Codeine (an opioid analgesic derived from an alkaloid). Official documents classify the medicine as a Composite Analgesic and Antispasmodic Agent, reflecting its dual action.

Q: Is Spasmalgin commonly used for headaches or migraines?

Official therapeutic indications for the analgesic component include the relief of mild to moderate pain, including headache. While the primary purpose is spasm-related discomfort, headache is a listed use. Migraine is not specifically mentioned in the official product information.

Q: Why do some people say Spasmalgin helps with menstrual cramps?

According to official product information, the pain-relieving components of this medicine are indicated for the relief of mild to moderate pain. This general therapeutic purpose may include addressing the pain experienced during menstrual cramps.

Q: What does 'contraindication' mean in relation to Spasmalgin?

The term 'contraindication' in official documents refers to a specific condition or circumstance where the medicine must not be used. It signifies that the risks associated with taking the medicine are considered too high for individuals with that particular health status.

Q: What official warnings or boxed statements exist for Spasmalgin?

Regulatory agencies issue warnings regarding the severe risks associated with this combination product. Key warnings include the potential for liver damage (hepatotoxicity) linked to Paracetamol and risks of dependence, addiction, and respiratory depression stemming from the Codeine component.

Q: Are there any known drug interactions for Spasmalgin with common cold medicines?

Official documents state that the Codeine ingredient can have additive effects with other medicines that cause drowsiness or sedation. This includes some ingredients found in common cold and flu medicines, such as certain antihistamines. The complete interactions section of the product information provides detailed guidance.

Q: Are there any reported interactions between Spasmalgin and herbal supplements?

Official drug labels caution against combining Spasmalgin with certain herbal supplements known as enzyme inducers. Specifically, common supplements like St. John’s Wort may affect the metabolic pathway that processes the Codeine component. The complete official interaction guidance should be reviewed for potential risks.

Q: Can people with a history of ulcers or stomach issues use Spasmalgin?

Regulatory warnings note that the Codeine component may obscure the diagnosis or clinical course of pre-existing digestive conditions. Regulatory documents note that caution is required in individuals with certain stomach issues, such as gastro-oesophageal reflux.

Q: What are the official recommendations for stopping Spasmalgin after short-term use?

Official documents advise that treatment should be for the shortest duration necessary. While used short-term, abrupt discontinuation is usually not an issue; however, if the medicine is taken long-term, slowly reducing the dose (tapering) may be recommended to avoid potential withdrawal reactions.

Storage and Disposal of Spasmalgin

Spasmalgin must be stored according to regulatory requirements to maintain its stability and efficacy.

Official Storage Conditions

Requirement	Condition
Temperature	Store below 25 C (ambient temperature).
Protection	Keep in the original package to protect from light and moisture.
Handling Rule	Do not freeze the product.
Child Safety	Mandatory: Keep strictly out of the sight and reach of children.

Disposal Instructions

Unused or expired Spasmalgin must not be disposed of in household trash or poured into the wastewater system (sink or toilet). To comply with pharmaceutical waste regulations and protect the environment, the medicine should be returned to a pharmacy or utilized through a designated local waste collection scheme for proper disposal.